公司核心财务与市场表现 - Doximity是美国领先的数字健康平台，市值48亿美元，TTM营收6.556亿美元，TTM净利润1.67亿美元，盈利能力强劲[1] - 截至8月7日交易日期，该股票一年回报率为-50%，8月10日收盘价为25.63美元[2] - 财报发布后次日股价飙升33%，但交易计划早在2月就已制定，不存在择时行为[4] - 最新季度营收增长7%至1.566亿美元，但自由现金流下降34%至3960万美元，应收账款三个月内增加超过3300万美元[5] - 管理层将现金流下降归因于收款时间安排，预计本季度开始恢复正常[5] 收入集中度与客户结构 - 127家制药和医院客户（每家年支出超过50万美元）贡献了上季度总营收的83%[6] - 整体净收入留存率为107%[6] - 投资者关系高级副总裁Perry Gold表示业务出现了“几个季度未见的增长动能”[6] 内部人交易与股权结构 - 董事Cabral在股价飙升日出售了7500股股票，交易依据2月19日通过的Rule 10b5-1交易计划自动执行，旨在避免非公开信息影响[3][4] - 出售后直接普通股持股降至3221股，但Cabral仍持有32.6万股直接衍生证券，保持重大长期利益[2][4] - 董事的实际风险敞口通常在于期权而非股票，这些期权确实存在[4]

Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established ...

Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established ...